These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17513157)

  • 1. [Factors affecting posttransfusion platelet efficiency "close relationship between patient and product"].
    Sensebé L
    Transfus Clin Biol; 2007 May; 14(1):90-3. PubMed ID: 17513157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
    Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
    Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
    McVey M; Cserti-Gazdewich CM
    Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO incompatible platelets: risks versus benefit.
    Dunbar NM; Ornstein DL; Dumont LJ
    Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and product factors affecting platelet transfusion results.
    Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
    Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion of platelets and plasma products.
    Menitove JE; Aster RH
    Clin Haematol; 1983 Feb; 12(1):239-66. PubMed ID: 6340882
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological aspects of the effectiveness/ineffectiveness of thrombocyte transfusions].
    Nagy S; Rácz Z
    Orv Hetil; 2001 Nov; 142(44):2415-20. PubMed ID: 11766234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs.
    Julmy F; Ammann RA; Taleghani BM; Fontana S; Hirt A; Leibundgut K
    Transfusion; 2009 Jan; 49(1):21-33. PubMed ID: 18774963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for managing refractoriness to platelet transfusions.
    Dan ME; Schiffer CA
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mini-review on platelet refractoriness.
    Rebulla P
    Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-transfusional platelet increment: effect of clinical factors].
    Muggenthaler KH; Böck M; Heim MU; Mempel W
    Beitr Infusionsther Transfusionsmed; 1994; 32():467-9. PubMed ID: 9480144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Sato A; Iseki T; Yamaguchi T; Tojo A; Asano S
    Bone Marrow Transplant; 2007 Sep; 40(6):523-8. PubMed ID: 17646845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory factors underlying refractoriness to platelet transfusions.
    Friedberg RC
    J Clin Apher; 1996; 11(3):143-8. PubMed ID: 8915819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for substitution therapy with thrombocytes].
    Bux J; Mueller-Eckhardt C
    Dtsch Med Wochenschr; 1993 Sep; 118(38):1367-70. PubMed ID: 8404478
    [No Abstract]   [Full Text] [Related]  

  • 19. How I do it: platelet support for refractory patients.
    Dzik S
    Transfusion; 2007 Mar; 47(3):374-8. PubMed ID: 17319815
    [No Abstract]   [Full Text] [Related]  

  • 20. Transfusion of apheresis platelets and ABO groups.
    Vox Sang; 2005 Apr; 88(3):207-21. PubMed ID: 15787735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.